Total Payments
$7,746
2024 Payments
$1,008
Companies
57
Transactions
388
Medicare Patients
1,676
Medicare Billing
$393,785
Payment Breakdown by Category
Food & Beverage$7,322 (94.5%)
Other$400.00 (5.2%)
Education$24.08 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,322 | 384 | 94.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $400.00 | 1 | 5.2% |
| Education | $24.08 | 3 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $1,139 | 47 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $883.78 | 36 | $0 (2022) |
| Lilly USA, LLC | $882.65 | 59 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $643.72 | 18 | $0 (2023) |
| Corcept Therapeutics | $460.31 | 27 | $0 (2024) |
| Dexcom, Inc. | $362.63 | 20 | $0 (2024) |
| Abbott Laboratories | $343.74 | 13 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $225.65 | 11 | $0 (2021) |
| Amarin Pharma Inc. | $204.80 | 13 | $0 (2021) |
| Medtronic, Inc. | $190.93 | 4 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,008 | 57 | Corcept Therapeutics ($133.28) |
| 2023 | $937.05 | 53 | Lilly USA, LLC ($213.50) |
| 2022 | $1,244 | 58 | Novo Nordisk Inc ($202.61) |
| 2021 | $1,208 | 60 | Novo Nordisk Inc ($254.51) |
| 2020 | $852.32 | 52 | AstraZeneca Pharmaceuticals LP ($219.82) |
| 2019 | $806.19 | 46 | Novo Nordisk Inc ($201.39) |
| 2018 | $990.69 | 37 | SANOFI-AVENTIS U.S. LLC ($452.82) |
| 2017 | $700.37 | 25 | AstraZeneca Pharmaceuticals LP ($345.03) |
All Payment Transactions
388 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $14.14 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 12/23/2024 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $25.48 | General |
| Category: Diabetes Care | ||||||
| 12/12/2024 | CeQur Corporation | CeQur Simplicity (Device) | Food and Beverage | Cash or cash equivalent | $16.12 | General |
| Category: Diabetes | ||||||
| 12/05/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $17.58 | General |
| Category: Obesity | ||||||
| 12/02/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $15.22 | General |
| Category: Endocrinology | ||||||
| 11/25/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $17.63 | General |
| Category: Neuropsychiatry | ||||||
| 11/18/2024 | IBSA Pharma Inc. | Tirosint (Drug), Licart | Food and Beverage | Cash or cash equivalent | $17.72 | General |
| Category: Endocrinology | ||||||
| 11/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: DIABETES | ||||||
| 11/01/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $16.74 | General |
| Category: NEUROSCIENCE | ||||||
| 10/28/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: Endocrinology | ||||||
| 10/28/2024 | Corcept Therapeutics | Korlym (Drug) | Education | In-kind items and services | $11.29 | General |
| Category: Endocrinology | ||||||
| 10/21/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $14.14 | General |
| Category: Cardiology | ||||||
| 10/14/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.43 | General |
| Category: Obesity | ||||||
| 09/30/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $14.72 | General |
| Category: NEUROSCIENCE | ||||||
| 09/26/2024 | PFIZER INC. | SOMAVERT (Drug), GENOTROPIN | Food and Beverage | In-kind items and services | $24.45 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 09/19/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $15.36 | General |
| Category: Endocrinology | ||||||
| 09/19/2024 | Corcept Therapeutics | Korlym (Drug) | Education | In-kind items and services | $11.29 | General |
| Category: Endocrinology | ||||||
| 09/09/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: Neuropsychiatry | ||||||
| 08/20/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $18.11 | General |
| Category: NEUROSCIENCE | ||||||
| 08/15/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $18.68 | General |
| Category: Diabetes | ||||||
| 08/09/2024 | Chiesi USA, Inc. | MYALEPT (Drug) | Food and Beverage | Cash or cash equivalent | $30.86 | General |
| Category: GENERALIZED LIPODYSTROPHY | ||||||
| 08/08/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: Endocrinology | ||||||
| 07/25/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: DIABETES MEDICINE | ||||||
| 07/22/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $16.98 | General |
| Category: Neuroscience | ||||||
| 07/15/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $22.95 | General |
| Category: Insulin Pump | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 357 | 1,103 | $178,860 | $86,397 |
| 2022 | 6 | 351 | 1,093 | $179,050 | $88,481 |
| 2021 | 8 | 415 | 1,219 | $201,790 | $102,940 |
| 2020 | 8 | 553 | 1,597 | $263,800 | $115,967 |
Total Patients
1,676
Total Services
5,012
Medicare Billing
$393,785
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 157 | 378 | $64,260 | $37,528 | 58.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 51 | 465 | $69,750 | $31,453 | 45.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 52 | 77 | $19,250 | $8,564 | 44.5% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 46 | 127 | $12,700 | $3,601 | 28.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 30 | 30 | $9,000 | $3,416 | 38.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 21 | 26 | $3,900 | $1,835 | 47.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 157 | 400 | $68,000 | $42,340 | 62.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 53 | 445 | $66,750 | $27,204 | 40.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 55 | 88 | $22,000 | $10,217 | 46.4% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 39 | 106 | $10,600 | $3,148 | 29.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 18 | 18 | $6,300 | $3,085 | 49.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 29 | 36 | $5,400 | $2,487 | 46.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 169 | 412 | $70,040 | $45,317 | 64.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 66 | 545 | $79,150 | $34,040 | 43.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 61 | 80 | $22,150 | $9,455 | 42.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 24 | 24 | $8,400 | $4,359 | 51.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 34 | 41 | $6,170 | $2,882 | 46.7% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 37 | 90 | $9,000 | $2,754 | 30.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 13 | 15 | $3,280 | $2,326 | 70.9% |
| 95250 | Ambulatory continuous glucose (sugar) monitoring for a minimum of 72 hours | Office | 2021 | 11 | 12 | $3,600 | $1,808 | 50.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 99 | 830 | $116,200 | $49,750 | 42.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 166 | 384 | $64,260 | $33,801 | 52.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 98 | 122 | $36,600 | $13,922 | 38.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 29 | 29 | $9,970 | $4,812 | 48.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 31 | 37 | $7,480 | $4,252 | 56.8% |
About Dr. Daisy Behman, MD
Dr. Daisy Behman, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Carteret, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1780694166.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daisy Behman, MD has received a total of $7,746 in payments from pharmaceutical and medical device companies, with $1,008 received in 2024. These payments were reported across 388 transactions from 57 companies. The most common payment nature is "Food and Beverage" ($7,322).
As a Medicare-enrolled provider, Behman has provided services to 1,676 Medicare beneficiaries, totaling 5,012 services with total Medicare billing of $393,785. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Carteret, NJ
- Active Since 08/09/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RE0101X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1780694166
Products in Payments
- FARXIGA (Drug) $883.78
- Ozempic (Drug) $646.36
- Korlym (Drug) $460.31
- SOLIQUA (Drug) $430.59
- JARDIANCE (Drug) $363.85
- TRULICITY (Drug) $257.96
- Dexcom G6 Transmitter (Medical Supply) $249.51
- FREESTYLE LIBRE (Device) $216.06
- Vascepa (Drug) $204.80
- JANUVIA (Drug) $187.10
- MINIMED 770G (Device) $167.97
- MOUNJARO (Drug) $154.19
- INGREZZA (Drug) $138.04
- Minimed 670G System (Device) $130.95
- BAQSIMI (Drug) $130.84
- RYBELSUS (Drug) $125.00
- Xultophy 100/3.6 (Drug) $125.00
- DEXCOM G6 TRANSMITTER (Device) $113.12
- SOLIQUA 100/33 (Biological) $111.69
- MYALEPT (Drug) $111.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.